Targeted NGS in fetuses with isolated and non-isolated CHD achieved a high diagnostic yield in our cohort, with an acceptable turnaround time for the prenatal setting. Our results have important implications for clinical management and genetic counseling. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

This study aimed to estimate the radiation dose and cancer risk to adults in England, the USA and Hong Kong associated with retrospectively and prospectively electrocardiogram (ECG)-gated coronary computed tomography angiography (CTA) using currently practised protocols in Hong Kong. The doses were simulated using the ImPACT spreadsheet. For retrospectively ECG-gated CTA with pitches of 0.2, 0.22 and 0.24, the effective doses were 27.7, 23.6 and 20.7 mSv, respectively, for males and 23.6, 20.0 and 18.8 mSv, respectively, for females. For prospectively ECG-gated CTA, the effective dose was 3.7 mSv for both males and females. A table of lifetime attributable risks (LAR) of cancer incidence was set up for the English population for the purpose of estimating cancer risk induced by low-dose radiation exposure, as previously reported for US and Hong Kong populations. From the tables, the LAR of cancer incidence for a representative 50-year-old subject was calculated for retrospectively ECG-gated CTA to be 0.112% and 0.227% for English males and females, respectively, 0.103% and 0.228% for US males and females, respectively, and was comparatively higher at 0.137% and 0.370% for Hong Kong males and females, respectively; for prospectively ECG-gated CTA, the corresponding values were calculated to be 0.014% and 0.035% for English males and females, respectively, and 0.013% and 0.036% for US males and females, respectively, and again were higher at 0.017% and 0.060% for Hong Kong males and females, respectively. Our study shows that prospectively ECG-gated CTA reduces radiation dose and cancer risks by up to 87% compared with retrospectively ECG-gated CTA.

Background: Advanced GC pts have limited treatment options and poor prognosis. Immune checkpoint inhibitors (ICIs) showed promising activities in pretreated pts, especially for those with high PD-L1 expression. Blockade of TGF-b pathway may enhance the tumor response to ICIs.Methods: This phase I study composed of a dose escalation and expansion (ESC & EXP) period in solid tumors and multiple clinical expansion cohorts. Based on findings of the ESC & EXP period, 30 mg/kg Q3W was determined as RP2D. In the GC clinical expansion cohort, pts who had progressed on or were intolerant to 2L standard therapies were given SHR-1701 at the RP2D. Prior ICIs were not allowed. Primary endpoint was ORR per RECIST v1.1.Results: 35 pts were enrolled: stage IV, 91.4%; 2L prior systemic therapies, 54.3%. By Apr 6, 2021, median SHR-1701 exposure was 12.0 wk (range 3.0-64.9). Of the 31 pts with post-baseline scan(s), 16 (51.6%) pts showed tumor shrinkage. 1 CR and 7 PR were achieved, and ORR was 25.8% (95% CI 11.9-44.6). 2 PR were not confirmed yet as there was no consequent scan after first PR as of data cutoff. Confirmed ORR was 19.4% (95% CI 7.5-37.5; 1 CR + 5 PR; ongoing responses: 66.7% [4/6]). DCR was 41.9% (95% CI 24.5-60.9). CBR (CR + PR + SD23 wk) was 25.8% (95% CI 11.9-44.6). Median PFS was 1.4 mo (95% CI 1.3-9.6), and 6-mo PFS rate was 38.7% (95% CI 22.0-55.1). Median OS was not reached yet. Exploratory analyses showed a trend towards favourable responses for pts with a PD-L1 CPS 5 (Table ). Most common TRAEs (incidence >10% in 35 pts) were rash, increased AST/ALT, decreased FT3 and pruritus. Incidence of irAEs was 45.7%. Grade 3 or 4 TRAEs occurred in 17.1% of pts, and no pts died due to TRAEs. Incidence of grade 3 irAEs was 11.4%. Table: 1375P Efficacy outcomes* in all patients and subgroups by PD-L1 expression All patients (N[31) CPS <5 (N[10) CPS ‡5 (N[9) ORR, n (%; 95% CI) 6 (19.4%; 7.

The aim of the study was to assess the reproducibility of vibrations recorded from the temporomandibular joint (TMJ) in a group of healthy subjects. The vibrations from TMJ were recorded bilaterally from 34 healthy subjects by electrovibratography in three sessions at intervals of 3 min and again after 1 week. The total integral of the vibration energy, the ratio of the integral between frequencies above 300 Hz and below 300 Hz (ratio of >300 Hz/<300 Hz), peak frequency, median frequency, peak amplitude and distance to centric occlusion position were calculated. Data were analysed with intraclass correlation coefficients (ICC) and two-way anova for repeated measures. All variables showed good to excellent reliability across different sessions (ICCday1 : 0·935-0·987; ICCday2 : 0·910-0·992) and across different days (ICC: 0·738-0·907). According to anova for repeated measures, all variables showed good reproducibility (P > 0·05) between sessions at the same day. There was no significant difference between the 2 days for the frequency-related variables including peak frequency (P = 0·083), median frequency (P = 0·188) and ratio of >300 Hz/<300 Hz (P = 0·26). There was a statistical difference between the 2 days for the intensity-related vibration variables including total integral (P = 0·045) and peak amplitude (P = 0·026). The wave patterns of the power-frequency spectra were qualitatively similar over both the sessions and days. Joint vibration analysis could provide a fast, non-invasive, and repeatable method to record the status of TMJ. Further studies are needed to identify the characteristic waveforms for different subgroups of temporomandibular disorders and to evaluate the possibility of diagnostic value.

Intrauterine insemination (IUI) is an effective, noninvasive, relatively simple and cheap method of infertility treatment. Many factors that affect IUI outcomes have been studied. However, there is no consensus about the optimal number of motile spermatozoa inseminated (NMSI) required for a reasonable chance of pregnancy after IUI. In this retrospective study, we aimed to assess the relationship between NMSI and the pregnancy rate after IUI with husband's spermatozoa. Couples who had either primary or secondary infertility for more than one year were recruited from the Department of Reproduction, Nanjing Maternity and Child Health Hospital, China, between January 2007 and December 2010. Overall, 1153 IUI cycles with husband's spermatozoa were performed in 645 women after ovarian stimulation. Factors that have previously been associated with a successful fertilisation after IUI were assessed. A total pregnancy rate of 13.88% was obtained. The pregnancy rate was only 4.05% if less than 2 × 10(6) motile spermatozoa were used, but this rose to 14.55% when more than 2 × 10(6) motile spermatozoa were inseminated. We therefore conclude that IUI can be performed when the NMSI exceeds 2 × 10(6) . With this recommendation, IUI with husband's spermatozoa can be used to treat many more infertile couples.

To explore the need for rescue intracytoplasmic sperm injection (ICSI) in cases of partial fertilisation failure during a conventional in vitro fertilisation cycle, rescue ICSI was performed for cycles with a fertilisation rate of <50%. The data were divided into three groups based on the fertilisation rate: group 1 (0%), group 2 (<25%) and group 3 (>25%). The impact of rescue ICSI on each group was then analysed in terms of ovum fertilisation, embryo development, embryo utilisation and selection of embryos for transfer. Rescue ICSI was performed on 1831 unfertilised oocytes from 313 cycles. The fertilisation rates for group 1, group 2 and group 3 were 74.66, 68.35 and 65.46%, and the rate of polyploidy in the three groups was 8.55, 11.33, and 14.47%. The percentage of embryos that can be transferred from rescue ICSI for group 2 was 38.33%, and this value was higher than those of the other two groups. It is concluded that rescue ICSI is not recommended for patients with an IVF rate of >25% as the procedure is associated with a greater risk and low returns. However, it is feasible to perform rescue ICSI for patients with IVF rates of <25%.

This study aimed to investigate the feasibility of the establishment of a human cancer xenograft model using samples from computed tomography (CT)-guided percutaneous biopsy. Fresh tumor tissues obtained from 10 cancer patients by CT-guided percutaneous biopsy were subcutaneously inoculated into NOD-Prkdcem26Il2rgem26Nju (NCG) mice to establish human patient-derived tumor xenograft (PDTX) models. The formation of first and second generation xenografts was observed, and tumor volume was recorded over time. Tumor tissue consistency between the PDTX model and primary tumors in patients was compared using H&E staining and immunohistochemistry. Pharmacodynamic tests of clinically used chemotherapeutic drugs were conducted on second generation xenografts, and their effects on tumor growth and body weight were observed. CT-guided percutaneous biopsy samples were successfully collected from 10 patients with advanced cancers. The PDTX model was established in mice using tumor samples obtained from 4 cancer patients, including one small cell carcinoma sample, two adenocarcinoma samples, and one squamous cell carcinoma sample. The success rate was 40%. The obtained PDTX model maintained a degree of differentiation, and morphological and structural characteristics were similar to primary tumors. The pharmacodynamic test of chemotherapeutic drugs in the PDTX model revealed a therapeutic effect on tumor growth, as expected. CT-guided percutaneous biopsy samples can be effectively used to establish a PDTX model, and test these chemotherapy regimens.

No abstract